Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE), American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA).

Advances in electrosurgical techniques have helped thousands of transcatheter valve patients
Toby Rogers, MD, associate professor of medicine at Georgetown University and an interventional cardiologist at MedStar, explains how electrosurgical procedures for transcaval access have helped large numbers of patients receive transcatheter heart valves who otherwise would have been disqualified due to anatomical issues.
3D echo guidance seeing increasing use in congenital heart surgery
Pei-Ni Jone, MD, FASE, director, echocardiography laboratory, Lurie Children’s Hospital Heart Center, member of the American Society of Echocardiography (ASE) Board, explains how 3D echo is being used to better plan, guide and follow up in congenital cardiac surgery.
ESC Congress broke new record with over 33,000 attendees
The European Society of Cardiology had nearly twice as many attendees as ACC this year, as the European meeting secures its place as the largest cardiology meeting in the world.
Johnson & Johnson’s PFA platform is both safe and effective, real-world data confirm
The Varipulse PFA platform, which has already received FDA and CE mark approval, was linked to an adverse event rate of just 0.6%.
Real-world data link semaglutide, tirzepatide to improved heart failure outcomes
GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.

Edward Fry, MD, is the 2022-23 ACC president.

Q&A: New ACC President Edward Fry discusses the past, present and future of cardiology

Fry joined us for an exclusive interview, discussing lessons learned during the pandemic, some key ways to address physician burnout and much more.

American Heart Association awards $10.6M to researchers investigating the long-term cardiovascular effects of COVID-19

The grants went to 11 different research teams in the United States and are expected to fund these projects for three years.

Links to the ACC.22 late-breaking clinical trials

Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C.

VIDEO: TAVR durability outperforms surgical valves

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

Nurses caring for a COVID-19 patient in the COVID unit at Banner University Medical Center in Phoenix.

An updated look at what cardiologists know about heart damage among COVID-19 patients

An international analysis published in Circulation and a new scientific statement from the American Heart Association both explore the latest data on heart complications associated with COVID-19.

Adam Greenbaum, MD, Emory, explains the CLASP TR trial of the Pascal clip device for transcatheter repair, which was a late-breaking ACC22 study.

VIDEO: Pascal effective in transcatheter repair of tricuspid valve regurgitation

Adam Greenbaum, MD, co-director of the Structural Heart and Valve Center at Emory University Hospital Midtown in Atlanta, explains details from the late-breaking CLASP TR trial at ACC.22.

Several ACC 2022 late-breaking trials may have impacts on clinical practice for interventional cardiology and structural heart. One trial compared FFR vs. IVUS guided PCI for intermediate coronary lesions. Photos by Dave Fornell

Key interventional cardiology takeaways from ACC.22

Several late-breaking clinical trials at ACC.22 will likely impact clinical practice. Below are summaries of a few key trials and their takeaways for interventional cardiology and structural heart interventions.

An implantable cardioverter defibrillator (ICD) and its associated leads viewed on a X-ray. Old leads are often abandon in veins and new ones added, but a new study of 1 million patients at ACC22 showed there is higher mortality if a device becomes infected and the leads are left behind. Image from RSNA.

VIDEO: Lowering mortality rates from infected EP implantable cardiac devices

Sean Pokorney, MD, director of the arrhythmia core lab, Duke Clinical Research Institute, assistant professor of Medicine, Duke University, discusses a late-breaking ACC 2022 study that shows mortality is higher in patients with implantable electrophysiology (EP) device infections where the leads are not explanted.

Cardiology Associations

Advances in electrosurgical techniques have helped thousands of transcatheter valve patients

3D echo guidance seeing increasing use in congenital heart surgery

ESC Congress broke new record with over 33,000 attendees

Johnson & Johnson’s PFA platform is both safe and effective, real-world data confirm

Real-world data link semaglutide, tirzepatide to improved heart failure outcomes